Clinical Trial Update: Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and tolerability of allogeneic blood-derived natural killer cells in cancers refractory to conventional therapy; the trial i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumor

Drugs mentioned

• Allogeneic blood-derived natural killer cells (natural killer cells)

Snippet

Sponsor: NKGen Biotech, Inc. | Conditions: Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer | Phase 1 | Status: COMPLETED